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Proteomic analysis‑based 
discovery of a novel biomarker 
that differentiates intestinal 
Behçet’s disease from Crohn’s 
disease
Jihye Park1,2,6, Daeun Jeong3,4,6, Youn Wook Chung3,5,6, Seunghan Han3,4, Da Hye Kim3, 
Jongwook Yu1,2, Jae Hee Cheon1,2,6* & Ji‑Hwan Ryu3,4,6*
Intestinal Behçet’s disease (BD) and Crohn’s disease (CD) present similar manifestations, but 
there are no specific diagnostic tests to differentiate them. We used a proteomic approach to 
discover novel diagnostic biomarkers specific to intestinal BD. Colon mucosa tissue samples were 
obtained from patients with intestinal BD or CD using colonoscopy‑guided biopsy of the affected 
bowel. Peptides from seven intestinal BD and seven CD patients were extracted and labeled using 
tandem mass tag (TMT) reagents. The labeled peptides were identified and quantified using liquid 
chromatography‑tandem mass spectrometry (LC–MS/MS). The proteins were further validated using 
immunohistochemical (IHC) analysis with tissue samples and an ELISA test with serum samples 
from 20 intestinal BD and 20 CD patients. Using TMT/LC–MS/MS‑based proteomic quantification, we 
identified 39 proteins differentially expressed between intestinal BD and CD. Beta‑2 glycoprotein 1 
(APOH) and maltase‑glucoamylase (MGAM) showed higher intensity in the IHC staining of intestinal 
BD tissues than in CD tissues. The serum MGAM level was higher in intestinal BD patients. Proteomic 
analysis revealed that some proteins were differentially expressed in patients with intestinal BD 
compared with those with CD. Differential MGAM expression in intestinal BD suggests its role as a 
potential novel diagnostic biomarker.
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HLA  Human leukocyte antigen
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Behçet’s disease (BD) is an idiopathic, chronic, relapsing, multi-systemic vasculitis characterized by recurrent oral 
or genital ulcers, arthritis, and ocular, dermal, neurovascular, and gastrointestinal  manifestations1,2. Intestinal BD 
is diagnosed when a patient with BD has clinical gastrointestinal symptoms and typical endoscopic  findings3. It 
is a very rare disease, but the prevalence of BD is the highest in countries located along the Silk Road stretching 
from Asia to the Mediterranean  countries4. Crohn’s disease (CD) is a chronic, relapsing, inflammatory, bowel 
disease (IBD) that may affect the gastrointestinal tract from the mouth to the anus. Once considered to be a 
Western disease, the incidence of CD has rapidly increased in East Asian countries, such as Japan, Korea, and 
Hong Kong, while plateauing in the  West5,6.
Both intestinal BD and CD often present similar gastrointestinal and extraintestinal manifestations, as well as 
endoscopic findings. Therefore, it is sometimes difficult to differentiate between these two diseases. Clinically, oral 
and genital ulcerations are more common in intestinal BD patients, and perianal lesions are more common in CD 
 patients7. However, both diseases develop nonspecific, waxing and waning, life-long gastrointestinal  symptoms8. 
Moreover, ocular and skin manifestations, and arthropathy, can occur in both  diseases9. Endoscopically, a typical 
intestinal BD ulcer is characterized by being single or few in number, round or oval in shape, deep, possessing a 
sharp margin, being larger than 10 mm, and showing localization to the ileocecal  valve10. The “atypical” intestinal 
BD ulcer without the systemic manifestations could be confused with CD. There have been several attempts to 
develop a diagnostic biomarker to differentiate between the two diseases, but there are practically no available 
tests because of several limitations.
Proteomic analysis is a promising technology that is a powerful tool for identifying biomarkers to help diag-
nose and choose personalized treatment. It allows high-throughput study of protein expression with high accu-
racy, sensitivity, and repeatability, and it enables the identification of molecular mechanisms that are responsible 
for the development of a specific  disease11,12. The tandem mass tag (TMT)-liquid chromatography-tandem mass 
spectrometric (LC–MS/MS) method has been recently developed to identify and quantify proteins. Although 
several studies have investigated colon mucosal biopsies using gel-based proteomic approaches to identify pro-
tein biomarkers that differentiate intestinal BD from  IBD13,14, no applicable biomarkers are currently available. 
Since gel-free proteomic approaches have several advantages compared to gel-based approaches, particularly for 
identifying membrane-bound and/or glycosylated large proteins (e.g., mucins)15, we used gel-free approaches to 
analyze intestinal BD proteomes in comparison with CD proteomes.
Here, we aimed to develop diagnostic biomarkers to differentiate between intestinal BD and CD. We employed 
a coupled TMT/LC–MS/MS-based method to identify proteins that were differentially expressed between patients 
with intestinal BD and CD.
Methods
Study population and sample collection. In total, 47 patients with intestinal BD and 47 patients with 
CD were recruited from the IBD Clinic of Severance Hospital, Seoul, Korea. Intestinal BD and CD were diag-
nosed according to clinical, histological, endoscopic, and radiological  criteria16,17. Exclusion criteria included 
indeterminate colitis, ulcerative colitis, intestinal tuberculosis, a history of malignancy, or insufficient available 
medical records. The intestinal BD ulcer type was defined according to the Korean Inflammatory Bowel Disease 
study group, and the CD phenotype was defined according to the Montreal  Classification18,19. The severity of 
intestinal BD was determined using the Disease Activity Index for Intestinal Behçet’s Disease (DAIBD) score, 
and CD severity was determined using the Crohn’s Disease Activity Index (CDAI)  score20,21.
The intestinal mucosa tissue samples were obtained from patients with intestinal BD or CD using colonos-
copy-guided biopsy of the affected bowel. The tissue and serum samples were preserved at −80 °C.
Informed consent was obtained from all individuals enrolled in this study. This study was approved by the 
Institutional Review Board of Yonsei University College of Medicine (IRB No: 2012-0039-030) and was conducted 
in accordance with the Declaration of Helsinki.
TMT sample processing and protein quantitation. For proteomic analysis, the colon mucosa tissue 
samples were lysed and labeled with tandem mass tag (TMT, Thermo Scientific, San Jose, CA, USA) according 
to the manufacturer’s instructions. The labeled peptide samples were pooled into a new vial and dried using 
SpeedVac (Thermo Scientific). The following processes, including strong cation exchange fraction and liquid 
chromatography (LC)-mass spectrometry (MS) and database searching, were performed by Poochon Scientific 
(Frederick, MD) as described  previously22. Briefly, TMT-multiplex labeled peptide mixture (100 µg protein/each 
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plex) fractionation was performed using an Agilent AdvanceBio Column and Agilent UHPLC 1290 system (Agi-
lent, Santa Clara, CA). LC/MS/MS analysis was performed using a Thermo Scientific Q-Exactive hybrid Quad-
rupole-Orbitrap Mass Spectrometer and Thermo Dionex UltiMate 3000 RSLCnano System (Thermo Scientific). 
Raw MS data files were searched against the human protein sequence databases obtained from the NCBI website 
using Proteome Discoverer 1.4 software (Thermo Scientific) based on the SEQUEST and percolator algorithms. 
The false positive discovery rate (FDR) was set at 5%. The resulting Proteome Discoverer Report from Poochon 
Scientific contained all assembled proteins with peptide sequences and peptide spectrum match counts (PSM#) 
and TMT-tag-based quantification ratios.
Immunohistochemistry (IHC). Formalin-fixed paraffin-embedded colonic biopsy sections from patients 
with intestinal BD (n = 20) and those with CD (n = 20) were stained with 39 antibodies and counterstained with 
hematoxylin–eosin. Antibodies against APOH (HPA003732) and MGAM (HPA002270) were purchased from 
Atlas Antibodies AB (Bromma, Sweden). Detailed antibody information, antibody dilution factors, and antigen 
retrieval methods are provided in Supplementary Table I. IHC analysis was performed as previously  described23. 
Primary antibodies (1:1000 dilution for anti-APOH and 1:2000 dilution for anti-MGAM) were applied over-
night at 4 °C. Staining was visualized using an Olympus BX43 microscope with the Olympus CellSens Entry 
software (Hamburg, Germany).
We used a semi-quantitative grading method to assess protein expression, as described  previously24. Briefly, 
100 × magnification was used to grade all fields for each sample, and the staining intensity was scored from 1 
to 3. Staining extent was scored from 1 to 4. The scores were multiplied together, and the final scores were clas-
sified as follows: 1–3, weak; 4–8, moderate; and 9–12, strong staining. Fisher’s exact test was used to assess the 
immunochemical scores for protein expression. In this particular test, values of p less than 0.2 were determined 
as a threshold for moving to the next validation test.
Enzyme‑linked immunosorbent assay (ELISA). Serum samples from patients with BD (n = 20) and 
those with CD (n = 20)—constituting an independent cohort of patients distinct from those providing samples 
for IHC staining—were analyzed using ELISA. The serum was diluted 1:50,000 for APOH and 1:200 for MGAM. 
ELISA was performed according to the manufacturer’s instructions using the APOH ELISA kit (KA0982, 
Abnova, Taipei, Taiwan) and the MGA ELISA kit (MBS2021345, MyBioSource, San Diego, CA).
Data analysis and statistical methods. A heat map was generated using the “limma” package for  R25. 
The fold changes of proteins and p values were calculated using linear regression in “limma.” The heat map 
was drawn using the heatmap.2 function in the “gplots” package for R (https:// CRAN.R- proje ct. org/ packa ge= 
gplots), and colors were changed using the “RColorBrewer” package for R (1.1-2. https:// CRAN.R- proje ct. org/ 
packa ge= RColo rBrew er). Volcano plots were plotted using GraphPad Prism 8 software. Data were expressed as 
the mean ± SEM. Student’s t-test was used for the statistical analysis of serum ELISA data. Statistical significance 
was set at p < 0.05.
Result
Descriptive patient characteristics. The colon mucosa tissue samples of 27 patients with intestinal BD 
and 27 patients with CD, and serum samples of 20 patients with intestinal BD and 20 patients with CD, were 
obtained. Detailed patient characteristics of the 94 patients are shown in Table 1. The mean age of the patients 
with intestinal BD and CD was 51. 0 ± 11.4 years and 36. 1 ± 16.0 years (p < 0.001), respectively, which were 
comparable to those obtained in a previous  study7. A total of 42.6% of the patients with intestinal BD and 74.5% 
of the patients with CD were men. The mean disease duration of intestinal BD and CD was 7.1 ± 6.0 years and 
8.0 ± 5.5 years, respectively. Oral ulcers, genital ulcers, skin manifestations, and joint manifestations were more 
common in patients with intestinal BD and perianal lesions were more common in those with CD. Intestinal 
BD ulcers were located in the ileocecal valve (74.5%), ascending colon (10.6%), and postoperative anastomosis 
site (14.6%). The intestinal BD ulcers occurred with the following frequency: solitary (48.9%), two (19.1%), and 
multiple (31.9%). The CD showed localization in the ileal (14.9%), colonic (2.1%), and ileocolic (83.0%) regions 
and could be characterized as non-stricturing and non-penetrating (63.0%), stricturing (15.2%), and penetrat-
ing (21.7%). The number of patients with a DAIBD score ≥ 40 was 35 (74.5%) and that of patients with a CDAI 
score ≥ 150 was 24 (51.1%).
Discovery of biomarker candidates using TMT/LC–MS/MS‑based proteomic approach. The 
colon mucosa tissue samples of patients with intestinal BD (n = 7) and those with CD (n = 7) were analyzed using 
a TMT/LC–MS/MS-based proteomic approach to identify intestinal BD-specific markers (Fig.  1). A total of 
3,266 proteins were quantitatively identified, and at least two identified peptides were detected for each protein 
(Fig. 2A). Logistic regression analysis showed that 39 proteins were significantly different between intestinal BD 
and CD patients (p < 0.05) (Fig. 2B). Among them, 34 proteins were overexpressed, and 5 proteins were under-
expressed in patients with intestinal BD compared to patients with CD (Table 2). The proteins were classified 
by cellular compartment (CC) based on gene ontology (GO) enrichment analysis using a functional annotation 
tool (DAVID Bioinformatics Resources, version 6.8) (Supplementary Table II). Among the top ten CC catego-
ries, 72.31% of GO items were associated with membrane-bounded vesicle (GO:0031988), extracellular region 
(GO:0005576), extracellular region (GO:0044421), extracellular exosome (GO:0070062), extracellular vesicle 
(GO:1903561), and extracellular organelle (GO:0043230), indicating that although there were a certain number 
of proteins from other cellular compartments such as the cytosol, nucleoplasm, mitochondrion, or cell junction, 
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a large portion of colon mucosal proteomes were composed of secretion-related proteins (Fig. 2C). Notably, 
APOH and MGAM were included in all six secretion-related CC categories in the GO analysis.
IHC validation of biomarker candidates. IHC analysis was performed to validate 39 candidate bio-
markers. A total of 40 colonic biopsy sections from patients with intestinal BD (n = 20) and CD (n = 20) were 
stained with each antibody and analyzed using a semi-quantitative grading method as described in the Methods 
section. Seven candidate proteins were selected based on their differential expression between intestinal BD 
and CD: maltase-glucoamylase (MGAM), beta-2 glycoprotein 1 (APOH), plasminogen (PLG), pro-interleukin 
16 (IL16), serine/arginine-rich splicing factor 3 (SRSF3), clusterin (CLU), and serine/threonine-protein phos-
phatase 4 catalytic subunit (PPP4C). Fisher’s exact test showed that APOH (p = 0.039) and MGAM (p = 0.192) 
levels were consistently higher in intestinal BD than in CD, suggesting that these two proteins might be dis-
tinctive biomarkers of intestinal BD distinguishing it from CD. There were no significant differences in the 
expression of PLG (p = 0.480), IL16 (p = 0.563), SRSF3 (p = 0.591), CLU (p = 1.000), or PPP4C (p = 0.450) between 
intestinal BD and CD. IHC analysis of the colon mucosa tissue obtained from patients with intestinal BD showed 
that stronger APOH immunoreactivity was detected in a portion of the lamina propria (Fig. 3A, lower panels), 
and the MGAM immunoreactive signal was exclusively present in the brush border membrane of the epithelium 
(Fig. 3B, lower panels), consistent with previous  findings26.
Serum ELISA validation of biomarker candidates. Since APOH and MGAM were included in all 
six secretion-related CC categories of GO analysis (Fig.  2C), we hypothesized that these proteins could also 
be detected in the blood. This notion was supported by several biochemical studies that identified APOH as a 
component of circulating plasma  lipoproteins27, and the fact that MGAM is found in brush border membrane 
 vesicles28. Both proteins were also recently detected in exosomes using in-depth proteomic  analyses29. Although 
there was no difference in APOH concentration between the two groups (Fig. 4A), serum concentrations of 
MGAM were statistically higher in patients with intestinal BD compared to those with CD (p < 0.05), when the 
two candidate biomarkers were further tested with serum ELISA in an independent validation cohort (intestinal 
BD, n = 20; CD, n = 20) (Fig. 4B). These results suggest that MGAM can be a specific, diagnostic biomarker of 
intestinal BD.
Table 1.  Baseline characteristics of the study patients. Variables are expressed as mean ± SEM or n (%). BD 
Behƈet’s disease, CD Crohn’s disease, TNF tumor necrosis factor, CDAI Crohn’s disease activity index, DAIBD 
disease activity index of Behƈet’s disease, SD standard deviation.
Variables Intestinal Behƈet’s disease (n = 47) Crohn’s disease (n = 47) p value
Age (years) 51.0 ± 11.4 36.1 ± 16.0  < 0.001
Males 20 (42.6%) 35 (74.5%) 0.001
Smoking history 12 (25.5%) 11 (23.4%) 0.810
Disease duration (years) 7.1 ± 6.0 8.0 ± 5.5 0.439
Charlson comorbidity index (≥ 2) 8 (17.0%) 2 (4.3%) 0.045
Extraintestinal manifestation
Oral ulcer 16 (41.0%) 0 (0.0%)  < 0.001
Genital ulcer 11 (28.2%) 0 (0.0%)  < 0.001
Skin manifestation 9 (23.1%) 0 (0.0%) 0.001
Joint manifestation 12 (30.8%) 2 (4.3%) 0.001
Eye manifestation 4 (10.3%) 3 (6.5%) 0.533
Vascular manifestation 1 (2.6%) 0 (0.0%) 0.459
Perianal lesion 1 (2.1%) 28 (59.6%)  < 0.001
Disease activity score
Remission (CDAI < 150) 23 (48.9%)
Mild (CDAI : 150–219) 10 (21.3%)
Moderate (CDAI : 220–450) 13 (27.7%)
Severe (CDAI > 450) 1 (2.1%)
Remission (DAIBD < 20) 7 (14.9%)
Mild (DAIBD : 20–39) 5 (10.6%)
Moderate (DAIBD : 40–74) 26 (55.3%)
Severe (DAIBD ≥ 75) 1 (2.1%)
Previous surgery 10 (21.3%) 11 (23.4%) 0.804
Previous medication
Corticosteroid 15 (31.9%) 15 (31.9%) 1.000
Immunomodulator 15 (31.9%) 21 (44.7%) 0.203
Anti-TNFɑ 4 (8.5%) 6 (12.8%) 0.503
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Analysis of the MGAM‑related pathway in the colon mucosa proteome. The DAVID functional 
annotation tool was used to identify the biological pathways of the colon mucosa proteome of intestinal BD and 
CD patients, in which MGAM could be involved. The Kyoto Encyclopedia of Genes and Genomes (KEGG) dem-
onstrated that 85 pathways were significantly enriched (p < 0.05) (Fig. 5A). Among them, MGAM was involved 
in three enriched pathways: metabolic pathways (hsa01100, 467 proteins), galactose metabolism (hsa00052, 19 
proteins), and starch and sucrose metabolism (hsa00500, 17 proteins). Unexpectedly, APOH was not related to 
any of the 85 enriched pathways.
To determine whether MGAM and APOH share biological functions, 3,266 proteins were divided into three 
GO annotation categories: cellular compartment (CC), molecular function (MF), and biological process (BP). 
Next, the categories containing MGAM or APOH were selected and compared. There were six CC categories, 
but no MF or BP categories, correlating with both MGAM and APOH as represented in Figs. 2C and 5B–D. 
This suggests that the physiological roles of MGAM and APOH might differ in the colon mucosa, but both are 
assumed to be secreted.
Predicted upstream regulators and disease‑related functions of MGAM in intestinal BD and 
CD. Ingenuity pathway analysis (IPA) was performed to predict canonical pathways, upstream regulators, 
and disease-related functions to gain more insight into the pathophysiological role of MGAM in intestinal BD 
and CD. As shown in Supplementary Fig. 1A, the only canonical pathway related to MGAM was enriched in 
“Glycogen degradation III.” Although absolute z scores (CD, − 0.302; BD, 0.302) were lower than the cut-off 
(z-score > 2), the pathway significantly differed between intestinal BD and CD (p < 0.000001). The pathway was 
predicted to be inhibited in CD and activated in intestinal BD (Supplementary Fig. 1B). Upstream regulator 
analysis revealed that the dexamethasone-related pathway was inactivated in CD compared to its status in intes-
tinal BD (Fig. 6A), but the medication history of corticosteroids (31.9%) was similar between the two patient 
groups participating in this study (Table 1). This result is consistent with previous observations that patients with 
CD require corticosteroid therapy more often than patients with intestinal  BD7. Comparison of the diseases and 
functional analyses of the two patient groups revealed that the activation of degranulation and the inactivation 
of genitourinary carcinogenesis were conserved, and the former is predicted to be more upregulated in intestinal 
BD than in CD, and the latter is more downregulated in CD than in intestinal BD (Fig. 6B).
Figure 1.  The colon mucosa tissue samples were obtained and analyzed using a TMT/LC–MS/MS-based 
approach for the discovery cohort (intestinal BD, n = 7; CD, n = 7). Candidate protein biomarker validation was 
performed using tissue IHC staining with the validation cohort 1 (intestinal BD, n = 20; CD, n = 20) and serum 
ELISA testing with the validation cohort 2 (intestinal BD, n = 20; CD, n = 20).
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Discussion
Accurate diagnosis of intestinal BD and CD is important for establishing proper treatment plans and predicting 
disease  prognosis30. Clinical, laboratory, and endoscopic approaches have limitations in differentiating between 
these two diseases. Gastrointestinal and systemic symptoms, elevated inflammatory markers, and endoscopic 
findings, such as asymmetric deep ulcers in the ileocecal valve, are often shared between the two diseases in 
clinical  practice31.
We quantified 3,266 proteins from the colon mucosa tissue samples, identified 39 novel diagnostic biomark-
ers, and validated the MGAM protein as a novel diagnostic biomarker using patient serum samples. To the best 
of our knowledge, this study is the first to use proteomics to identify a diagnostic marker that can differentiate 
intestinal BD from CD.
Quantitative proteomic analysis using isobaric chemical labeling, including super-stable isotope labeling with 
amino acids in cell culture, isobaric tags for relative and absolute quantitation, or TMT, is emerging as a highly 
effective approach with good quantification performance and reproducibility for profiling new biomarkers in 
numerous  diseases32. These relatively new proteomic techniques enable the discovery of diagnostic biomarkers 
by providing methods not only for peptide identification, but also for the quantification of biological samples. 
Thus far, they have been applied to  IBD33 or intestinal  TB24, but not to intestinal BD. We identified 39 potential 
novel diagnostic biomarkers using quantitative proteomic analysis, and validated MGAM as a biomarker for 
differentiating intestinal BD from CD.
MGAM is involved in carbohydrate digestion in the small intestine. MGAM deficiency has been reported 
in congenital diarrheal  diseases34. MGAM and sucrase-isomaltase (SI) have identical exon structures. They 
are anchored in the small intestinal mucosal brush border and hydrolyze substrates to  glucose35. Romach et al. 
reported a trinitrobenzene sulfonic acid-induced colitis rat model that showed a loss of SI expression and 
Figure 2.  Proteomic characterization of 14 samples (seven from patients with intestinal BD and seven from 
patients with CD) using TMT-10plex labeling-based quantitative proteomics. (A) A heat map showing the 
relative abundance of 3266 proteins identified across two groups of human intestinal samples. The color key 
indicates the relative abundance of each protein (− 2 to 2) across 14 samples. (B) Volcano plot demonstrating 
fold changes in protein abundance between intestinal BD and CD. The x-axis represents the log2 ratio, and the 
y-axis represents significant differences (-log10 of p value). Proteins showing significantly altered expression 
(p < 0.05) are colored in magenta, and include the top ten up- or down-regulated proteins (fold change > 1.5). (C) 
A pie diagram showing cellular localization of human colon mucosa proteomes classified by the top ten cellular 
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 activity36. Lackeyram et al. observed that a dextran sodium sulfate-induced colitis piglet model revealed decreased 
maximal specific activities of MGAM and  SI37. Here, the tissue expression and serum concentrations of MGAM 
were lower in patients with CD patients than in those with intestinal BD. Our IPA analysis also predicted that 
the MGAM-related “glycogen degradation III” pathway was inactivated in CD (Supplementary Fig. 1A,B). Con-
sistent with our findings, the involvement of the small intestine is relatively common in CD than in intestinal 
BD, resulting in digestive problems and nutrient malabsorption. Thus, differential MGAM expression may be 
related to different clinical manifestations between intestinal BD and CD, which should be further validated.
MGAM has been shown to be important in neutrophil biology but not in  lymphocytes38,39. We identified 
MGAM in the colon mucosa tissue samples, but MGAM was also detected in the serum samples. The detected 
serum MGAM may be secreted from the gastrointestinal tract or contained in neutrophils. All five degranulation-
related pathways (degranulation, degranulation of cells, degranulation of phagocytes, degranulation of neutro-
phils, and degranulation of granulocytes) enriched in the disease or functional annotations with high activation 
z-score indicated that MGAM might be involved in the degranulation process in which mast cell activation is 
essential. Although little is known regarding the degranulation in intestinal BD, degranulation signaling in IBD 
has been implicated in the regulation of inflammatory responses in the gastrointestinal tract, where the largest 
Table 2.  Candidate protein biomarkers for differential diagnosis between intestinal Behƈet’s disease and 
Crohn’s disease. BD Behƈet’s disease, CD Crohn’s disease, AUC area under the curve.
UniProt Entry name Protein (full name) UniProt Accession # Gene name Ratio (CD/BD) p value AUC 
APOC1_HUMAN Apolipoprotein C-I P02654 APOC1 0.43 0.015 0.7755
IGHG4_HUMAN Immunoglobulin heavy constant gamma 4 P01861 IGHG4 0.54 0.024 0.8163
PLMN_HUMAN Plasminogen P00747 PLG 0.61 0.042 0.8776
AFAM_HUMAN Afamin P43652 AFM 0.61 0.015 0.7347
RHG30_HUMAN Rho GTPase-activating protein 30 Q7Z6I6 ARHGAP30 0.61 0.017 0.7347
A1AG2_HUMAN Alpha-1-acid glycoprotein 2 P19652 ORM2 0.62 0.040 0.7959
MGA_HUMAN Maltase-glucoamylase, intestinal O43451 MGAM 0.63 0.031 0.7551
CRCC2_HUMAN Putative ciliary rootlet coiled-coil protein 2 H7BZ55 CROCC2 0.66 0.008 0.8367
ZA2G_HUMAN Zinc-alpha-2-glycoprotein P25311 AZGP1 0.66 0.040 0.7755
ACE_HUMAN Angiotensin-converting enzyme P12821 ACE 0.67 0.015 0.8016
APOH_HUMAN Beta-2-glycoprotein 1 P02749 APOH 0.68 0.033 0.8061
GILT_HUMAN Gamma-interferon-inducible lysosomal thiol reductase P13284 IFI30 0.69 0.019 0.7959
NHRF1_HUMAN Na( +)/H( +) exchange regulatory cofactor NHE-RF1 O14745 SLC9A3R1 0.69 0.008 0.7959
VTDB_HUMAN Vitamin D-binding protein P02774 GC 0.70 0.045 0.7347
CLUS_HUMAN Clusterin P10909 CLU 0.70 0.049 0.7347
LOX5_HUMAN Arachidonate 5-lipoxygenase P09917 ALOX5 0.71 0.040 0.7959
LRRF1_HUMAN Leucine-rich repeat flightless-interacting protein 1 Q32MZ4 LRRFIP1 0.71 0.033 0.7959
JUPI1_HUMAN Jupiter microtubule associated homolog 1 Q9UK76 JPT1 0.72 0.049 0.8163
IL16_HUMAN Pro-interleukin-16 Q14005 IL16 0.72 0.021 0.7755
C1S_HUMAN Complement C1s subcomponent P09871 C1S 0.73 0.017 0.8776
ASH2L_HUMAN Set1/Ash2 histone methyltransferase complex subunit ASH2 Q9UBL3 ASH2L 0.76 0.049 0.4959
SRSF2_HUMAN Serine/arginine-rich splicing factor 2 Q01130 SRSF2 0.76 0.030 0.8571
SRSF3_HUMAN Serine/arginine-rich splicing factor 3 P84103 SRSF3 0.77 0.037 0.7959
ITA5_HUMAN Integrin alpha-5 P08648 ITGA5 0.77 0.025 0.7755
PP4C_HUMAN Serine/threonine-protein phosphatase 4 catalytic subunit P60510 PPP4C 0.77 0.033 0.7347
AKP13_HUMAN A-kinase anchor protein 13 Q12802 AKAP13 0.77 0.045 0.7551
TARA_HUMAN TRIO and F-actin-binding protein Q9H2D6 TRIOBP 0.77 0.013 0.8571
LMNB1_HUMAN Lamin-B1 P20700 LMNB1 0.78 0.037 0.7755
TOIP2_HUMAN Torsin-1A-interacting protein 2 Q8NFQ8 TOR1AIP2 0.80 0.020 0.9184
ACAP2_HUMAN Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 2 Q15057 ACAP2 0.82 0.045 0.8163
PLEC_HUMAN Plectin Q15149 PLEC 0.82 0.038 0.7755
SMRC2_HUMAN SWI/SNF complex subunit SMARCC2 Q8TAQ2 SMARCC2 0.83 0.033 0.8571
LRRF2_HUMAN Leucine-rich repeat flightless-interacting protein 2 Q9Y608 LRRFIP2 0.84 0.048 0.7857
NU205_HUMAN Nuclear pore complex protein Nup205 Q92621 NUP205 0.87 0.030 0.8776
IMPA2_HUMAN Inositol monophosphatase 2 O14732 IMPA2 1.22 0.038 0.7245
DMD_HUMAN Dystrophin P11532 DMD 1.26 0.049 0.7959
PERE_HUMAN Eosinophil peroxidase P11678 EPX 1.44 0.034 0.8163
LOX15_HUMAN Arachidonate 15-lipoxygenase P16050 ALOX15 1.53 0.048 0.7755
LEG10_HUMAN Galectin-10 Q05315 CLC 1.59 0.027 0.8367
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Figure 3.  APOH and MGAM expression in the colonic mucosa. Tissue sections from patients with CD or BD 
stained with antibodies against APOH (A) or MGAM (B). The selected areas denoted by white boxes in left 
panels (original magnification, 100 ×) are enlarged in the right panels (200 ×). Scale bar, 200 µm.
Figure 4.  Serum APOH and MGAM protein expression detected using ELISA in intestinal BD patients (A) and 
CD patients (B). Results are mean ± SEM; ***p < 0.001. n = 20 patients per each group.
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population of mast cells in the body  resides40–43. Higher MGAM levels were detected in intestinal BD patients 
than in CD patients, and this was related to innate immunity pathogenesis. Further studies are required to 
understand how MGAM influences immune cell degranulation and the resulting gut inflammation. Moreover, 
it would be valuable to determine whether MGAM levels correlate with the disease activity of intestinal BD.
Here, MGAM was shown to differentiate BD from CD with an area under the curve of 0.805 (95% confidence 
interval, 0.665–0.945), 85% sensitivity, and 70% specificity at a cut-off of 150 ng/mL (Fig. 7). However, further 
studies with a larger sample size are warranted to validate our data on the role of MGAM in chronic enterocolitis 
and to understand its molecular mechanism in depth. In addition, a significant proportion of our CD cohort 
population had perianal involvement, which distinguishes CD from intestinal BD. Perianal lesions in CD occur 
more frequently in Korea than in Western countries, but the ideal cohort population for the development of 
diagnostic biomarkers should present common or resembling clinical, endoscopic, radiologic, and histologic 
features of the two diseases. Future studies using such a cohort will be needed to validate MGAM as a distin-
guishing diagnostic biomarker. Finally, the measurement of MGAM levels in a variety of inflammatory diseases 
such as ulcerative colitis and intestinal tuberculosis could be worthwhile.
In summary, we used TMT-based proteomic quantification to identify 39 candidate proteins that were dif-
ferentially expressed between intestinal BD and CD. Then, we selected APOH and MGAM proteins as possible 
biomarkers for intestinal BD based on the results of IHC staining and semi-quantitative grading. Finally, we 
suggest that the levels of MGAM protein in patient serum can potentially be used to differentially diagnose 
intestinal BD from CD.
Figure 5.  MGAM and APOH characterization in human colon mucosal proteomes. (A) Significant biological 
pathways enriched among 3,266 proteins identified by TMT are represented as bar graphs (p < 0.05) with the 
MGAM-containing categories highlighted in red. Venn diagrams showing numbers of MGAM-and APOH-
containing categories classified by cellular compartment (B), molecular function (C), and biological process (D) 
based on functional annotation with gene ontology (GO) analysis.
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